Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

Researchers explain how a drug that helps patients with neurological issues walk may also provide a surprising boost for the ...

Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

Aging brings many changes that can be unpleasant, from losing mobility to needing help with tasks that used to be easy. For those with Alzheimer's disease and other forms of ...

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to ...